Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-10-03
2006-10-03
Zeman, Robert A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C424S136100, C424S159100, C424S160100, C435S069100, C435S069700, C435S975000, C530S300000, C530S350000, C530S380000, C530S387300, C530S390100, C536S023100, C536S023400, C536S023530
Reexamination Certificate
active
07115262
ABSTRACT:
This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker.
REFERENCES:
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5298419 (1994-03-01), Masuho et al.
patent: 5587455 (1996-12-01), Berger et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5614612 (1997-03-01), Haigwood et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5643756 (1997-07-01), Kayman et al.
patent: 5695927 (1997-12-01), Masuho et al.
patent: 5756674 (1998-05-01), Katinger et al.
patent: 5767260 (1998-06-01), Whitlow et al.
patent: 5817767 (1998-10-01), Allaway et al.
patent: 5843454 (1998-12-01), Devico et al.
patent: 5843882 (1998-12-01), Boyd et al.
patent: 5856456 (1999-01-01), Whitlow et al.
patent: 5922325 (1999-07-01), Tilley et al.
patent: 5925741 (1999-07-01), Gershoni
patent: 6020468 (2000-02-01), Gershoni
patent: 6107019 (2000-08-01), Allaway et al.
patent: 6143876 (2000-11-01), Gershoni
patent: 6329202 (2001-12-01), Gershoni
patent: 6410318 (2002-06-01), Gershoni
patent: 2003/0039663 (2003-02-01), Devico et al.
patent: 0 739 904 (1990-06-01), None
patent: 0 739 904 (1996-10-01), None
patent: WO 97/47318 (1997-12-01), None
patent: WO 98/36087 (1998-08-01), None
patent: WO 99/64073 (1999-12-01), None
Bowie et al (Science, 1990, 257:1306-1310).
Bork (Genome Research, 2000, 10:398-400).
Alkhatib et al., “CC CKR5: A RANTES, MIP-1α, MIP-1βReceptor as a Fusion Cofactor for Macrophage-Tropic HIV-1,”Science272:1955-1958, Jun. 28, 1996.
Allaway et al., “Synergistic Inhibition of HIV-1 Envelope-Mediated Cell Fusion by CD4-Based Molecules in Combination with Antibodies to gp120 or gp41,”AIDS Research and Human Retroviruses9:581-587, 1993.
Balter, “Revealing HIV's T Cell Passkey,”Science280:1833-1834, Jun. 19, 1998.
Bandres et al., “Human Immunodeficiency Virus (HIV) Envelope Binds to CXCR4 Independently of CD4, and Binding Can Be Enhanced by Interaction with Soluble CD4 or by HIV Envelope Deglycosylation,”J. Virol.72:2500-2504, Mar. 1998.
Boots et al., “Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries,”AIDS Research and Human Retroviruses13:1549-1559, 1997.
Broder and Berger, “Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+T-cell lines vs. primary macrophages,”Proc. Natl. Acad. Sci. USA92:9004-9008, Aug. 1995.
Broder et al., “The Block to HIV-1 Envelope Glycoprotein-Mediated Membrane Fusion in Animal Cells Expressing Human CD4 Can Be Overcome by a Human Cell Component(s),”Virology13:483-491, 1993.
Broder and Berger, “CD4 Molecules with a Diversity of Mutations Encompassing the CDR3 Region Efficiently Support Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Cell Fusion,”J. Virol.67:913-926, Feb. 1993.
Byrn et al., “Biological properties of a CD4 immunoadhesin,”Nature344:667-670, Apr. 12, 1990.
Cao and Suresh, “Bispecific Antibodies as Novel Bioconjugates,”Bioconjugate Chem.9:635-645, 1998.
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy,”Nature337:525-531, Feb. 9, 1989.
Cheong et al., “Affinity enhancement of bispecific antibody against two different epitopes in the same antigen,”Biochem. Biophys. Res. Comm.173:795-800, Dec. 31, 1990.
Cook and Wood, “Chemical synthesis of bispecific monoclonal antibodies: potential advantages in immunoassay systems,”J. Immunol. Meth.171:227-237, 1994.
D'Souza et al., “Evaluation of Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates by Neutralization Assays: Performance Criteria for Selecting Candidate Antibodies for Clinical Trials,”J. Infect. Dis.175:1056-1062, 1997.
Feng et al., “HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor,”Science272:872-877, May. 10, 1996.
Fu et al., “Isolation and characterization of a monoclonal antibody that inhibits HIV-1 infection,”Microbes and Infection1:677-684, 1999.
Ho et al., “Conformational Epitope on gp120 Important in CD4 Binding and Human Immunodeficiency Virus Type 1 Neutralization Identified by a Human Monoclonal Antibody,”J. Virol.65:489-493, Jan. 1991.
Idziorek and Klatzmann, “Construction of CD4-Based Chimeric Molecules by Chemical Cross-Linking,”AIDS Research. and Human Retroviruses7:529-536, 1991.
Kang et al., “Identification of a New Neutralizing Epitope Conformationally Affected by the Attachment of CD4 to gp120,”J. Immunol.151:449-457, Jul. 1, 1993.
Kwong et al., “Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody,”Nature393:648-659, Jun. 18, 1998.
Mondor et al., “Human Immunodeficiency Virus Type 1 Attachment of HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans,”J. Virol.72:3623-3634, May 1998.
Neri et al., “High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs),”J. Mol. Biol.246:367-373, 1995.
Nussbaum et al., “Fusogenic Mechanisms of Enveloped-Virus Glycoproteins Analyzed by a Novel Recombinant Vaccinia Virus-Based Assay Quantitating Cell Fusion-Dependent Reporter Gene Activation,”J. Virol.68:5411-5422, Sep. 1994.
Ridgway et al., “Knobs-into holes' engineerig of antibody CH3 domains for heavy chain heterodimerization,”Prot. Eng.9:617-621, 1996.
Rizzuto et al., “A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Rector Binding,”Science280:19491953, Jun. 19, 1998.
Robert-Guroff et al., “HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex,”Nature316-72-74, Jul. 4, 1985.
Root et al., “Protein Design of an HIV-1 Entry Inhibitor,”Science291:884-888, Feb. 2, 2001.
Satrentau and Moore, “Conformational Changes Induced in the Human Immunodeficiency Virus Envelope Glycoprotein by Soluble CD4 Binding,”J. Exp. Med174:407-415, Aug. 1991.
Sullivan et al., “CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1gp120 Glycoprotein: Consequences for Virus Entry and Neutralization,”J. Virol.72:4694-4703, Jun. 1998.
Thali et al., “Characteriza6tion of Conserved Human Immunodeficiency Virus Type 1 gp120 Neutralization Epitopes Exposed upon gp120-CD4 Binding,”J. Virol.67:3978-3988, Jul. 1993.
Traunecker et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells,”EMBO J.10:3655-3659, Dec. 1991.
Traunecker et al., “Janusin: new molecular design for bispecific reagents,”Int. J. CancerSupplement 7:51-52, 1992.
Trkola et al., “CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5,”Nature384:184-187, Nov. 14, 1996.
Vodicka et al., “Indicator Cell Lines for Detection of Primary Strains of Human and Simian Immunodeficiency Viruses,”Virology233:193-198, 1997.
Wu et al., “CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5,”Nature384:179-183, Nov. 14, 1996.
Wyatt et al., “Involvement of the V1/V2 Variable Loop Structure in the Exposure of Human Imunodeficiency Virus Type 1 gp
Berger Edward A.
Del Castillo Christie M.
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
Zeman Robert A.
LandOfFree
Chimeric protein for prevention and treatment of HIV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric protein for prevention and treatment of HIV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric protein for prevention and treatment of HIV infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3631141